A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection

A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection

This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in virologically suppressed participants with chronic HBV infection.

Inclusion Criteria:

• Chronic hepatitis B infection
• Positive test for HBsAg for more than 6 months prior to randomization
• HBsAg titer greater than or equal to (>/=) 250 international units per milliliter (IU/mL) at Screening
• Treatment with any nucleoside/nucleotide analogue for >/= 1 year with ongoing entecavir and/or tenofovir treatment at randomization and for at least 3 months prior to randomization
• HBV DNA less than (<) 90 IU/mL for at least the preceding 6 months
• HBeAg positive at randomization and for at least 6 months prior to randomization

Exclusion Criteria:

• Pregnant or lactating women
• Documented history of HBV genotype D
• History or other evidence of bleeding from esophageal varices
• History of decompensated liver disease, chronic liver disease other than HBV infection, or any evidence of metabolic liver disease
• Positive test for hepatitis A, hepatitis C, or human immunodeficiency virus (HIV)
• Documented history of hepatitis D infection
• History of or suspicion of hepatocellular carcinoma
• History of immunologically mediated disease
• History of organ transplantation
• History of thyroid disease
• Significant acute infection